JP2019511526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511526A5 JP2019511526A5 JP2018553357A JP2018553357A JP2019511526A5 JP 2019511526 A5 JP2019511526 A5 JP 2019511526A5 JP 2018553357 A JP2018553357 A JP 2018553357A JP 2018553357 A JP2018553357 A JP 2018553357A JP 2019511526 A5 JP2019511526 A5 JP 2019511526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- oxo
- fluoro
- methyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112726A JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321311P | 2016-04-12 | 2016-04-12 | |
| US62/321,311 | 2016-04-12 | ||
| PCT/US2017/026134 WO2017180389A1 (en) | 2016-04-12 | 2017-04-05 | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112726A Division JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511526A JP2019511526A (ja) | 2019-04-25 |
| JP2019511526A5 true JP2019511526A5 (https=) | 2020-05-14 |
| JP6911047B2 JP6911047B2 (ja) | 2021-07-28 |
Family
ID=58548919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553357A Expired - Fee Related JP6911047B2 (ja) | 2016-04-12 | 2017-04-05 | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
| JP2021112726A Active JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112726A Active JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11298362B2 (https=) |
| EP (1) | EP3442529B1 (https=) |
| JP (2) | JP6911047B2 (https=) |
| KR (1) | KR102418765B1 (https=) |
| CN (1) | CN109310684B (https=) |
| AU (1) | AU2017249078B2 (https=) |
| CA (1) | CA3020875A1 (https=) |
| ES (1) | ES2881801T3 (https=) |
| MX (1) | MX380779B (https=) |
| RU (1) | RU2747788C2 (https=) |
| WO (1) | WO2017180389A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| EP3442528B1 (en) * | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer |
| JP6911047B2 (ja) | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| IL257225A (en) * | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| KR20210005714A (ko) * | 2018-05-06 | 2021-01-14 | 아얄라 파마큐티컬즈 아이엔씨. | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 |
| WO2019226667A1 (en) * | 2018-05-25 | 2019-11-28 | Nantomics, Llc | Comprehensive molecular profiling with proteomic and genomic analyses |
| CN112535686B (zh) * | 2019-09-20 | 2022-06-14 | 山东轩竹医药科技有限公司 | 激酶抑制剂的新用途 |
| CN113880809B (zh) * | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| WO2023109875A1 (en) * | 2021-12-16 | 2023-06-22 | Edigene Therapeutics (Beijing) Inc. | Biomarkers for colorectal cancer treatment |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001232A3 (en) | 1996-12-23 | 2001-02-28 | Elan Pharmaceuticals Inc San F | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
| EP1117778A2 (en) | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| JP5385904B2 (ja) | 2007-08-14 | 2014-01-08 | イーライ リリー アンド カンパニー | γ−セクレターゼ阻害剤 |
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| ES2822665T3 (es) | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| AU2014309199B2 (en) | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JP6911047B2 (ja) | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
| EP3442528B1 (en) * | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| SG11201901325UA (en) | 2016-08-31 | 2019-03-28 | Lilly Co Eli | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
-
2017
- 2017-04-05 JP JP2018553357A patent/JP6911047B2/ja not_active Expired - Fee Related
- 2017-04-05 CA CA3020875A patent/CA3020875A1/en active Pending
- 2017-04-05 EP EP17717990.0A patent/EP3442529B1/en active Active
- 2017-04-05 AU AU2017249078A patent/AU2017249078B2/en active Active
- 2017-04-05 CN CN201780036170.7A patent/CN109310684B/zh active Active
- 2017-04-05 US US16/093,123 patent/US11298362B2/en active Active
- 2017-04-05 RU RU2018138627A patent/RU2747788C2/ru active
- 2017-04-05 MX MX2018012457A patent/MX380779B/es unknown
- 2017-04-05 ES ES17717990T patent/ES2881801T3/es active Active
- 2017-04-05 WO PCT/US2017/026134 patent/WO2017180389A1/en not_active Ceased
- 2017-04-05 KR KR1020187032285A patent/KR102418765B1/ko not_active Expired - Fee Related
-
2021
- 2021-07-07 JP JP2021112726A patent/JP7288482B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511526A5 (https=) | ||
| JP7288482B2 (ja) | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 | |
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP7278331B2 (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| JP2019511529A5 (https=) | ||
| JP2013507415A5 (https=) | ||
| JP2014132009A5 (https=) | ||
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2012522837A5 (https=) | ||
| JP2015524847A (ja) | 小細胞肺がんを治療するためのベンゾジアゼピン | |
| JP2015517523A5 (https=) | ||
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| TW202131917A (zh) | 併用醫藥 | |
| JP2011513429A (ja) | 改善された抗癌治療法 | |
| KR20150136073A (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| Navarro et al. | American Association for Cancer Research (AACR)-106th Annual Meeting. Philadelphia, Pennsylvania, USA-April 18-22, 2015 | |
| CN102105148B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| CN101287469A (zh) | 5－(2－氯苯基)－1,2－二氢－7－氟－8－甲氧基－3－甲基－吡唑并[3,4－b][1,4]苯并二氮杂䓬的给药方案 | |
| CN102105147B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| AU2018234141A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| NZ786609A (en) | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |